Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type (Buphenyl, Ravicti, Ammonul, and Others), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type (Buphenyl, Ravicti, Ammonul, and Others), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder that causes excessive ammonia buildup in the blood (hyperammonemia). When ammonia levels are too high, it is toxic and affects the nervous system. This signs and symptoms may also include lack of energy and appetite, an uncontrollable breathing rate, body temperature, unusual body movements, seizures, or coma. This form can be found in both males and females. OTC is caused by genetic changes in the OTC gene, and it is inherited in an X-linked manner. Complications from ornithine transcarbamylase deficiency may include developmental delay and intellectual disability. Progressive liver damage may also occur.

Market Dynamics

Increasing inorganic growth strategies by market players is expected to drive the market growth over the forecast period. For instance, in September 2022, GENFIT, a late-stage biopharmaceutical company, announced it had entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, is a clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. This agreement significantly expands GENFIT’s pipeline with VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD).

Increasing product launches by key players for ornithine transcarbamylase (OTC) deficiency treatment is expected to drive the market growth over the forecast period. For instance, in September 2022, Medunik USA, a pharmaceutical company, announced the launch of Pheburane oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB). Pheburane is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs).

Key features of the study:

• This report provides in-depth analysis of the global ornithine transcarbamylase (OTC) deficiency treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ornithine transcarbamylase (OTC) deficiency market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestlé, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc. , Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, and Translate Bio, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ornithine transcarbamylase (OTC) deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ornithine transcarbamylase (OTC) deficiency treatment market.

Detailed Segmentation:

• Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type:
• Buphenyl
• Ravicti
• Ammonul
• Others
• Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration:
• Oral
• Intravenous
• Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Horizon Therapeutics Plc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Bausch Health Companies Inc
• Danone
• Nestlé
• Ultragenyx Pharmaceutical
• Arcturus Therapeutics, Inc
• Abbott
• Swedish Orphan Biovitrum AB
• Acer Therapeutics Inc
• Assertio Holdings, Inc
• iECURE
• Translate Bio, Inc.

“*” marked represents similar segmentation in other categories in the respective section.